Tim Benke

Dr. Tim Benke

orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2005 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
VDVolodymyr I Dzhala
Volodymyr I Dzhala
DTDelia M Talos
Delia M Talos
DSDan A Sdrulla
Dan A Sdrulla
ABAudrey C Brumback
Audrey C Brumback
GMGregory C Mathews
Gregory C Mathews
KSKevin J Staley
Kevin J Staley

23 February 2007 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
BCBrandon J. Cornejo
Brandon J. Cornejo
MMMichael H. Mesches
Michael H. Mesches
SCSteven Coultrap
Steven Coultrap
MBMichael D. Browning
Michael D. Browning
TBTim Benke
Tim Benke

22 November 2011 in Cell Research
Verified
Journal Article
Open access
PDF file
XLXinjian Liu
Xinjian Liu
FLFang Li
Fang Li
ESElizabeth A Stubblefield
Elizabeth A Stubblefield
BBBarbara Blanchard
Barbara Blanchard
TRToni L Richards
Toni L Richards
CLChuan-Yuan Li
Chuan-Yuan Li
Transplantation of exogenous dopaminergic neuron (DA neurons) is a promising approach for treating Parkinson's disease (PD). However, a major stumbling block has been the lack of a reliable source of donor DA neurons. Here we show that a combination of five transcriptional factors Mash1, Ngn2, Sox2, Nurr1, and Pitx3 can directly and effectively reprogram human fibroblasts into DA neuron-like cells. The reprogrammed cells stained positive for various markers for DA neurons. They also showed characteristic DA uptake and production properties. Moreover, they exhibited DA neuron-specific electrophysiological profiles. Finally, they provided symptomatic relief in a rat PD model. Therefore, our directly reprogrammed DA neuron-like cells are a promising source of cell-replacement therapy for PD.

13 September 2020 in BMJ Paediatrics Open
Verified
Journal Article
Open access
PDF file
CFCary Fu
Cary Fu
DADallas Armstrong
Dallas Armstrong
EMEric Marsh
Eric Marsh
DLDavid Lieberman
David Lieberman
KMKathleen Motil
Kathleen Motil
TBTim Benke
Tim Benke
Background Rett syndrome (RTT) is a severe neurodevelopmental disorder with complex medical comorbidities extending beyond the nervous system requiring the attention of health professionals. There is no peer-reviewed, consensus-based therapeutic guidance to care in RTT. The objective was to provide consensus on guidance of best practice for addressing these concerns. Methods Informed by the literature and using a modified Delphi approach, a consensus process was used to develop guidance for care in RTT by health professionals. Results Typical RTT presents early in childhood in a clinically recognisable fashion. Multisystem comorbidities evolve throughout the lifespan requiring coordination of care between primary care and often multiple subspecialty providers. To assist health professionals and families in seeking best practice, a checklist and detailed references for guidance were developed by consensus. Conclusions The overall multisystem issues of RTT require primary care providers and other health professionals to manage complex medical comorbidities within the context of the whole individual and family. Given the median life expectancy well into the sixth decade, guidance is provided to health professionals to achieve current best possible outcomes for these special-needs individuals.

1 September 1996 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
IBIris Bresink
Iris Bresink
TBTim Benke
Tim Benke
VCValerie J. Collett
Valerie J. Collett
ASAndrew Seal
Andrew Seal
CPChris G. Parsons
Chris G. Parsons
GCGraham L. Collingridge
Graham L. Collingridge
The actions of the uncompetitive N‐methyl‐d‐aspartate (NMDA) receptor antagonists, memantine (1‐amino‐3,5‐dimethyladamantane) and (+)‐MK‐801 ((+)‐5‐methyl‐10,11‐dihydro‐5H‐dibenzo[a,d]cyclohepten‐5,10‐imine maleate, dizocilpine), on recombinant NMDA receptors has been studied by use of the whole‐cell patch clamp technique. Human embryonic kidney (HEK) 293 cells were transiently transfected with different NMDA receptor subunit combinations (NR1a/NR2A, NR1a/NR2B and NR1a/NR2D). A mutant form of the green fluorescent protein (GFP) was cotransfected with the NMDA receptor subunits to enable the visualization of transfected cells. Memantine (0.3–30 μm) blocked L‐glutamate (100 μm)‐mediated currents in a concentration‐dependent manner in NR1a/NR2A, NR1a/NR2B and NR1a/NR2D transfected cells with IC50 values (at −70 mV) of 0.93±0.15 μm, 0.82±0.12 μm and 0.47±0.06 μm (mean±s.e. mean), respectively. The memantine‐induced block was strongly voltage‐dependent. Alteration of the holding potential from −70 mV to +60 mV resulted in an e‐fold increase in the IC50 values per 30–33 mV change in membrane potential, for all 3 subunit combinations investigated. The kinetics of the actions of memantine (30 μm) were investigated for the NR1a/2A combination, in 6 cells (13–15 determinations). At −70 mV, the block and recovery from block were both best described by two exponentials with time‐constants of 201±23 ms (81±2%) and 3.9±0.6 s and 597±94 ms (18±1%) and 18.6±2.4 s, respectively. The predominant effect of depolarization was to increase the weight of the faster recovery time‐constant. Kinetic analysis suggests that these results are consistent with previously proposed Markov models. (+)‐MK‐801 was studied briefly for comparative purposes. (+)‐MK‐801 (200 nM) preferentially blocked NMDA receptor currents (at −70 mV) in NR1a/NR2A and NR1a/NR2B (82±10% and 93±2% depressions) compared to NR1a/NR2D (38±7%) transfected cells. (+)‐MK‐801 appeared to be less voltage‐dependent than memantine on all three receptor combinations. In conclusion, memantine was a voltage‐dependent antagonist of recombinant rat NMDA receptors expressed in HEK 293 cells but showed little selectivity between the subunits investigated. Its actions on these recombinant receptor combinations are similar to its actions on native NMDA receptors.

22 September 2020 in BMJ Paediatrics Open
Verified
Journal Article
Open access
PDF file
CFCary Fu
Cary Fu
DADallas Armstrong
Dallas Armstrong
EMEric Marsh
Eric Marsh
DLDavid Lieberman
David Lieberman
KMKathleen Motil
Kathleen Motil
TBTim Benke
Tim Benke
Background: Rett syndrome (RTT) is a severe, progressive neurodevelopmental disorder with multisystem comorbidities that evolve across a patient’s lifespan requiring attentive coordination of subspecialty care by primary care providers. A comprehensive, up-to-date synthesis of medical comorbidities in RTT would aid care coordination and anticipatory guidance efforts by healthcare providers. Our objective was to review and summarise published evidence regarding prevalence of RTT medical comorbidities across all relevant organ systems.Methods: Search of PubMed from January 2000 to July 2019 was performed using the search terms (Rett and MECP2 AND patient) OR (Rett and MECP2 AND cohort). Articles reporting the prevalence of clinical findings in RTT were assessed with respect to the size and nature of the cohorts interrogated and their relevance to clinical care.Results: After review of over 800 records, the multisystem comorbidities of RTT were summarised quantitatively from 18 records comprising both retrospective and prospective cohorts (31–983 subjects). Neurological comorbidities had the highest prevalence, occurring in nearly all individuals with gastrointestinal and orthopaedic concerns almost as prevalent as neurological. With the exception of low bone mineral content which was relatively common, endocrine comorbidities were seen in only around one-third of patients. Although more prevalent compared with the general population, cardiac conduction abnormalities were the least common comorbidity in RTT.Conclusions: Effective care coordination for RTT requires knowledge of and attention to multiple comorbidities across multiple unrelated organ systems. Many issues common to RTT can potentially be managed by a primary care provider but the need for sub-specialist referral can be anticipated. Since the median life expectancy extends into the sixth decade with evolving subspecialty requirements throughout this time, paediatric providers may be tasked with continued coordination of these comorbidities or transitioning to adult medicine and specialists with experience managing individuals with complex medical needs.